CD38 and neoplasm: Functional studies further revealed that #5-CD38-IgG1 was as potent as daratumumab and isatuximab in mediating ADCC and ADCP of CD38-positive tumor cells, while CDC activity was comparable to isatuximab and PCD induction was comparable to daratumumab.